Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Borchmann

Showing results (161-170 of 252) with videos related to

Pageof 26
Sort By:
The Lancet. Oncology|November 15, 2017
Incorporation of brentuximab vedotin into first-line treatment of advanced classical Hodgkin's lymphoma: final analysis of a phase 2 randomised trial by the German Hodgkin Study GroupDennis A Eichenauer, Annette Plütschow, Stefanie Kreissl, et al.
European Journal of Haematology|January 28, 2022
Impact of timing and precision of histopathological diagnosis on outcomes of patients with Burkitt lymphoma and high-grade B-cell lymphomaClaus Moritz Graef, Philipp Gödel, Philipp Falderbaum, et al.
Advances in Radiation Oncology|March 10, 2023
Radiation Therapy in the German Hodgkin Study Group HD 16 and HD 17 Trials: Quality Assurance and Dosimetric Analysis for Hodgkin Lymphoma in the Modern EraMichael Oertel, Dominik Hering, Nina Nacke, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 22, 2016
Cancer-Related Fatigue in Patients With and Survivors of Hodgkin Lymphoma: The Impact on Treatment Outcome and Social ReintegrationKarolin Behringer, Helen Goergen, Horst Müller, et al.
Blood|April 19, 2015
A phase 1 study of the bispecific anti-CD30/CD16A antibody construct AFM13 in patients with relapsed or refractory Hodgkin lymphomaAchim Rothe, Stephanie Sasse, Max S Topp, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 25, 2012
Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapyBertrand Coiffier, Barbara Pro, H Miles Prince, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 20, 2013
ABVD in older patients with early-stage Hodgkin lymphoma treated within the German Hodgkin Study Group HD10 and HD11 trialsBoris Böll, Helen Görgen, Michael Fuchs, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 11, 2018
Outcome of Patients With Early-Stage Infradiaphragmatic Hodgkin Lymphoma: A Comprehensive Analysis From the German Hodgkin Study GroupStephanie Sasse, Helen Goergen, Annette Plütschow, et al.
Blood Advances|January 27, 2026
Rapid molecular response kinetics to anti-PD1 based first-line treatment of Hodgkin lymphoma in the GHSG NIVAHL trialJan-Michel Heger, Julia Mattlener, Peter Herhaus, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 24, 2020
Health-Related Quality of Life in Patients With Hodgkin Lymphoma: A Longitudinal Analysis of the German Hodgkin Study GroupStefanie Kreissl, Horst Müller, Helen Goergen, et al.
Pageof 26

Showing results (161-170 of 252) with videos related to

Sort By:
Pageof 26
The Lancet. Oncology|November 15, 2017
Incorporation of brentuximab vedotin into first-line treatment of advanced classical Hodgkin's lymphoma: final analysis of a phase 2 randomised trial by the German Hodgkin Study GroupDennis A Eichenauer, Annette Plütschow, Stefanie Kreissl, et al.
European Journal of Haematology|January 28, 2022
Impact of timing and precision of histopathological diagnosis on outcomes of patients with Burkitt lymphoma and high-grade B-cell lymphomaClaus Moritz Graef, Philipp Gödel, Philipp Falderbaum, et al.
Advances in Radiation Oncology|March 10, 2023
Radiation Therapy in the German Hodgkin Study Group HD 16 and HD 17 Trials: Quality Assurance and Dosimetric Analysis for Hodgkin Lymphoma in the Modern EraMichael Oertel, Dominik Hering, Nina Nacke, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 22, 2016
Cancer-Related Fatigue in Patients With and Survivors of Hodgkin Lymphoma: The Impact on Treatment Outcome and Social ReintegrationKarolin Behringer, Helen Goergen, Horst Müller, et al.
Blood|April 19, 2015
A phase 1 study of the bispecific anti-CD30/CD16A antibody construct AFM13 in patients with relapsed or refractory Hodgkin lymphomaAchim Rothe, Stephanie Sasse, Max S Topp, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 25, 2012
Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapyBertrand Coiffier, Barbara Pro, H Miles Prince, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 20, 2013
ABVD in older patients with early-stage Hodgkin lymphoma treated within the German Hodgkin Study Group HD10 and HD11 trialsBoris Böll, Helen Görgen, Michael Fuchs, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 11, 2018
Outcome of Patients With Early-Stage Infradiaphragmatic Hodgkin Lymphoma: A Comprehensive Analysis From the German Hodgkin Study GroupStephanie Sasse, Helen Goergen, Annette Plütschow, et al.
Blood Advances|January 27, 2026
Rapid molecular response kinetics to anti-PD1 based first-line treatment of Hodgkin lymphoma in the GHSG NIVAHL trialJan-Michel Heger, Julia Mattlener, Peter Herhaus, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 24, 2020
Health-Related Quality of Life in Patients With Hodgkin Lymphoma: A Longitudinal Analysis of the German Hodgkin Study GroupStefanie Kreissl, Horst Müller, Helen Goergen, et al.
Pageof 26